Nov 14, 2019
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
Oct 28, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 18, 2019
ESSA Announces Changes to its Board of Directors
Sep 28, 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
Sep 19, 2019
ESSA to Present at Ladenburg Thalmann Healthcare Conference
Sep 10, 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
Sep 05, 2019
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Aug 27, 2019
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
Aug 23, 2019
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
Aug 21, 2019
U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer
Aug 14, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
Jul 31, 2019
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
Jul 30, 2019
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
Jul 15, 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
Jul 08, 2019
ESSA Provides Update on Court Hearing
Jun 26, 2019
ESSA Provides an Update to the Acquisition of Realm Therapeutics
Jun 25, 2019
ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders
Jun 21, 2019
ESSA Pharma to Hold Annual Shareholders' Meeting and Announces Three Realm-Nominated Directors
May 10, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019
May 04, 2019
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting